



Monday April 14, 2025

Dear EML Secretariat,

I am writing on behalf of Migraine Canada, the only national charity in Canada committed to improving the lives of Canadians with migraine and other headache disorders through advocacy, awareness, education, research and support.

We have read with extreme interest the applications:

A.10 eletriptan naproxen, migraine

A.13 fremanezumab, high frequency and chronic migraine

I.2 amitriptyline - migraine prophylaxis

I.3 bisoprolol - migraine prophylaxis

I.7 ibuprofen - acute migraine treatment

I.10 Prednisolone, sumatriptan and verapamil - cluster headache

Migraine Canada supports these applications, as they address a significant unmet need within the general population. Migraine and cluster headache are highly disabling chronic conditions that remain underdiagnosed and undertreated. Introducing more effective treatments for their management represents an important step toward improving care in many countries.

Our organization is fully committed to supporting this initiative and is available to provide any additional information or assistance as needed. We look forward to the positive impact this development will have on the global health landscape.

Sincerely,

A handwritten signature in dark ink, appearing to read "WGerhart", with a stylized, cursive-like script.

Wendy Gerhart
Executive Director
Migraine Canada